- Home
- SLRX vs ONCO Comparison
SLRX vs ONCO Comparison
Compare SLRX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- ONCO
- Stock Information
- Founded
- SLRX N/A
- ONCO 2018
- Country
- SLRX United States
- ONCO United States
- Employees
- SLRX N/A
- ONCO N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- ONCO Health Care
- Exchange
- SLRX Nasdaq
- ONCO Nasdaq
- Market Cap
- SLRX 1.8M
- ONCO 1.8M
- IPO Year
- SLRX N/A
- ONCO 2022
- Fundamental
- Price
- SLRX $0.92
- ONCO $4.61
- Analyst Decision
- SLRX
- ONCO
- Analyst Count
- SLRX 0
- ONCO 0
- Target Price
- SLRX N/A
- ONCO N/A
- AVG Volume (30 Days)
- SLRX 3.5M
- ONCO 224.3K
- Earning Date
- SLRX 08-08-2025
- ONCO 06-12-2025
- Dividend Yield
- SLRX N/A
- ONCO N/A
- EPS Growth
- SLRX N/A
- ONCO N/A
- EPS
- SLRX N/A
- ONCO N/A
- Revenue
- SLRX N/A
- ONCO $1,925,313.00
- Revenue This Year
- SLRX N/A
- ONCO N/A
- Revenue Next Year
- SLRX N/A
- ONCO N/A
- P/E Ratio
- SLRX N/A
- ONCO N/A
- Revenue Growth
- SLRX N/A
- ONCO 153.70
- 52 Week Low
- SLRX $0.45
- ONCO $3.82
- 52 Week High
- SLRX $7.20
- ONCO $1,190.00
- Technical
- Relative Strength Index (RSI)
- SLRX 55.98
- ONCO 41.73
- Support Level
- SLRX $0.61
- ONCO $3.92
- Resistance Level
- SLRX $1.33
- ONCO $4.73
- Average True Range (ATR)
- SLRX 0.14
- ONCO 0.74
- MACD
- SLRX 0.03
- ONCO -0.03
- Stochastic Oscillator
- SLRX 52.84
- ONCO 22.07
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.